Adial PharmaceuticalsADIL
13F holders, Q3 2024 (September 30)11holders −4
1new positions
4sold out
1famous investor
$1.00avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, down 4 from Q2 2024. 1 opened new positions and 4 sold out. The largest holders were Manchester Capital Management LLC ($48K), Geode Capital Management, LLC ($45K) and Citadel Advisors ($33K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A205
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $27K |
| Exits | 4 | $73K |
All 13F filers, Q2 2024 → Q3 2024: 55,501 shares bought and 145,128 shares sold, net −89,627 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Manchester Capital Management LLC | 0.01% | No change | 48,097 | $48K |
| Geode Capital Management, LLC | 0.00% | Add +75.7% | 45,466 | $45K |
| Citadel Advisors | 0.00% | Add +34.5% | 33,270 | $33K |
| BlackRock, Inc. | 0.00% | — | 27,770 | $28K |
| Two Sigma Securities, LLC | 0.00% | New | 27,115 | $27K |
| UBS Group AG | 0.00% | Reduce -94.7% | 4,404 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -30.0% | 3,943 | $4K |
| 1620 Investment Advisors, Inc. | 0.00% | No change | 3,600 | $4K |
| Morgan Stanley | 0.00% | Add +692.3% | 309 | $309 |
| Bank of America Corp. | 0.00% | Reduce -92.5% | 52 | $52 |
| Abound Wealth Management | 0.00% | No change | 27 | $27 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.